{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:37Z","timestamp":1791357397731,"version":"4.3.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s11910-010-0100-z","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T22:43:15Z","timestamp":1269988995000},"page":"180-189","source":"Crossref","is-referenced-by-count":22,"title":["Hypocretin Ligand Deficiency in Narcolepsy: Recent Basic and Clinical Insights"],"prefix":"10.1007","volume":"10","author":[{"given":"Cayde","family":"Ritchie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Okuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanbayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,1]]},"reference":[{"key":"100_CR1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.smrv.2005.03.004","volume":"9","author":"S Nishino","year":"2005","unstructured":"Nishino S, Kanbayashi T: Symptomatic narcolepsy, cataplexy, and hypersomnia, and their implications in the hypothalamic hypocretin\/orexin system. Sleep Med Rev 2005, 9:269\u2013310.","journal-title":"Sleep Med Rev"},{"key":"100_CR2","doi-asserted-by":"crossref","unstructured":"\u2022 Nishino S: Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007, 8:373\u2013399. The author examines the centrality of hypocretin neurotransmission impairment to the pathophysiologic mechanism in narcolepsy and the potential of ligand replacement as a relevant therapeutic option in view of the results of recent animal studies.","DOI":"10.1016\/j.sleep.2007.03.008"},{"key":"100_CR3","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","volume":"59","author":"E Mignot","year":"2002","unstructured":"Mignot E, Lammers GJ, Ripley B, et al.: The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59:1553\u20131562.","journal-title":"Arch Neurol"},{"key":"100_CR4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0006-3223(03)00349-4","volume":"54","author":"S Nishino","year":"2003","unstructured":"Nishino S: The hypocretin\/orexin system in health and disease. Bio Psychiatry 2003, 54:87\u201395.","journal-title":"Bio Psychiatry"},{"key":"100_CR5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0301-0082(96)00070-6","volume":"52","author":"S Nishino","year":"1997","unstructured":"Nishino S, Mignot E: Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997, 52:27\u201378.","journal-title":"Prog Neurobiol"},{"key":"100_CR6","unstructured":"Nishino S, Taheri S, Black J, et al.: The neurobiology of sleep in relation to mental illness. In Neurobiology of Mental Illness. Edited by Charney DS, Nestler EJ. New York: Oxford University Press; 2004:1160\u20131179."},{"key":"100_CR7","first-page":"811","volume":"27","author":"RA Espana","year":"2004","unstructured":"Espana RA, Scammell TE: Sleep neurobiology for the clinician. Sleep 2004, 27:811\u2013820.","journal-title":"Sleep"},{"key":"100_CR8","first-page":"620","volume":"20","author":"MS Aldrich","year":"1997","unstructured":"Aldrich MS, Chervin RD, Marlow BA: Value of the multiple sleep latency test (MSLT) for diagnosis of narcolepsy. Sleep 1997, 20:620\u2013629.","journal-title":"Sleep"},{"key":"100_CR9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/sleep\/15.3.217","volume":"15","author":"T Takeuchi","year":"1992","unstructured":"Takeuchi T, Miyasist A, Sasaki Y, et al.: Isolated sleep paralysis elicited by sleep interruption. Sleep 1992, 15:217\u2013225.","journal-title":"Sleep"},{"key":"100_CR10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","volume":"92","author":"T Sakurai","year":"1998","unstructured":"Sakurai T, Amemiya A, Ishii M, et al.: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573\u2013585.","journal-title":"Cell"},{"key":"100_CR11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","volume":"95","author":"L Lecca De","year":"1998","unstructured":"De Lecca L, Kilduff TS, Peyron C, et al.: The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998, 95:322\u2013327.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"100_CR12","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","volume":"18","author":"C Peyron","year":"1998","unstructured":"Peyron C, Tighe DK, van den Pol AN, et al.: Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998, 18:9996\u201310015.","journal-title":"J Neurosci"},{"key":"100_CR13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","volume":"98","author":"L Lin","year":"1999","unstructured":"Lin L, Faraco J, Li R, et al.: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365\u2013376.","journal-title":"Cell"},{"key":"100_CR14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","volume":"98","author":"RM Chemelli","year":"1999","unstructured":"Chemelli RM, Willie JT, Sinton CM, et al.: Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437\u2013451.","journal-title":"Cell"},{"key":"100_CR15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","volume":"355","author":"S Nishino","year":"2000","unstructured":"Nishino S, Ripley B, Overeem S, et al.: Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39\u201340.","journal-title":"Lancet"},{"key":"100_CR16","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","volume":"6","author":"C Peyron","year":"2000","unstructured":"Peyron C, Faraco J, Rogers W, et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991\u2013997.","journal-title":"Nat Med"},{"key":"100_CR17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ana.1130","volume":"50","author":"S Nishino","year":"2001","unstructured":"Nishino S, Ripley B, Overeen S, et al.: Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001, 50:381\u2013388.","journal-title":"Ann Neurol"},{"key":"100_CR18","volume-title":"The International Classification of Sleep Disorders Diagnostic and Coding Manual, edn 2","author":"American Academy of Sleep Medicine","year":"2005","unstructured":"American Academy of Sleep Medicine: The International Classification of Sleep Disorders Diagnostic and Coding Manual, edn 2. Winchester, IL: American Academy of Sleep Medicine; 2005."},{"key":"100_CR19","doi-asserted-by":"crossref","unstructured":"Honda Y: Clinical features of narcolepsy: Japanese experience. In HLA in Narcolepsy. Edited by Honda Y, Juji T. New York: Springer-Verlag; 1988:24\u201357.","DOI":"10.1007\/978-3-642-83387-8_3"},{"key":"100_CR20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1365-2869.2002.00284.x","volume":"11","author":"T Kanbayashi","year":"2002","unstructured":"Kanbayashi T, Inoue Y, Chiba S, et al.: CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002, 11:91\u201393.","journal-title":"J Sleep Res"},{"key":"100_CR21","doi-asserted-by":"crossref","first-page":"11189","DOI":"10.1212\/01.wnl.0000175219.01544.c8","volume":"65","author":"AM Blouin","year":"2005","unstructured":"Blouin AM, Thannickal TC, Worley PF, et al.: Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology 2005, 65:11189\u201311192.","journal-title":"Neurology"},{"key":"100_CR22","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1212\/01.WNL.0000168173.71940.ab","volume":"65","author":"A Crocker","year":"2005","unstructured":"Crocker A, Espana RE, Papdopoulou M, et al.: Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005, 65:1184\u20131188.","journal-title":"Neurology"},{"key":"100_CR23","doi-asserted-by":"crossref","unstructured":"\u2022 Honda M, Eriksson KS, Zhang S, et al.: IGFBP3 colocalizes with and regulates hypocretin (orexin). PLoS One 2009, 4:e4254. This article discusses the recent identification of IGFBP3, thereby underscoring selective hypocretin cell death, as opposed to transcription\/biosynthesis or hypocretin peptide processing problems, as the cause of hypocretin deficiency.","DOI":"10.1371\/journal.pone.0004254"},{"key":"100_CR24","first-page":"201","volume":"18","author":"M Billiard","year":"1989","unstructured":"Billiard M, Laaberki MF, Reygrobellet C, et al.: Elevated antibodies to streptococcal antigens in narcoleptic subjects. Sleep Res 1989, 18:201.","journal-title":"Sleep Res"},{"key":"100_CR25","doi-asserted-by":"crossref","unstructured":"\u2022 Dauvilliers Y, Arnulf I, Mignot E: Narcolepsy with cataplexy. Lancet 2007, 369:499\u2013511. This article discusses the possibility that transient autoimmune reaction in the CNS coincides with disease onset despite the failure to find typical autoimmune pathologies or to implicate neuron-specific\/organ-specific autoimmune antibodies or IgG reactive to prepro-hypocretin or cleavage products in narcoleptic patients.","DOI":"10.1016\/S0140-6736(07)60237-2"},{"key":"100_CR26","doi-asserted-by":"crossref","unstructured":"\u2022 Aran A, Lin L, Nevsimalova S, et al.: Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009, 32(8):979\u2013983. This recent, significant study evaluated Streptococcus pyogenes and Helicobacter pylori infections as triggers for narcolepsy. The study compared 200 hypocretin-deficient narcolepsy patients with 200 age-matched controls to find that patients exhibited significantly higher immune response markers close to narcolepsy onset. These findings underscore the probability that streptococcal infections are significant environmental triggers for narcolepsy.","DOI":"10.1093\/sleep\/32.8.979"},{"key":"100_CR27","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1212\/WNL.50.2_Suppl_1.S16","volume":"50","author":"E Mignot","year":"1998","unstructured":"Mignot E: Genetic and familial aspects of narcolepsy. Neurology 1998, 50:S16\u2013S22.","journal-title":"Neurology"},{"key":"100_CR28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1034\/j.1399-0039.2000.560508.x","volume":"56","author":"H Hohjoh","year":"2000","unstructured":"Hohjoh H, Nakayama T, Ohashi J, et al.: Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with human narcolepsy. Tissue Antigens 2000, 56:446\u2013448.","journal-title":"Tissue Antigens"},{"key":"100_CR29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.mp.4000911","volume":"6","author":"Y Dauvilliers","year":"2001","unstructured":"Dauvilliers Y, Neidhart E, Lecendreux M, et al.: MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry 2001, 6:367\u2013372.","journal-title":"Mol Psychiatry"},{"key":"100_CR30","doi-asserted-by":"crossref","unstructured":"\u2022 Miyagawa T, Kawashima M, Nishida N, et al.: Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet 2008, 40:1324\u20131328. These familial and twin studies examining gene polymorphisms associated with narcolepsy specifically indicate that the predictive genes of narcolepsy may exacerbate narcolepsy sleep phenotype and\/or engage mechanisms of hypocretin cell death.","DOI":"10.1038\/ng.231"},{"key":"100_CR31","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/j.humimm.2004.07.209","volume":"65","author":"MH Park","year":"2004","unstructured":"Park MH, Roh EY, Park H, et al.: Association of TNF-alpha gene promoter polymorphism with narcolepsy-cataplexy in Koreans. Hum Immunol 2004, 65:S110.","journal-title":"Hum Immunol"},{"key":"100_CR32","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1034\/j.1399-0039.2003.00068.x","volume":"61","author":"S Wieczorek","year":"2003","unstructured":"Wieczorek S, Gencik M, Rujescu D, et al.: TNFA promoter polymorphisms and narcolepsy. Tissue Antigens 2003, 61:437\u2013442.","journal-title":"Tissue Antigens"},{"key":"100_CR33","first-page":"R1018","volume":"276","author":"JB Dickenstein","year":"1999","unstructured":"Dickenstein JB, Moldofsky H, Lue FA, et al.: Intracerebroventricular injection of TNF-alpha promotes sleep and is recovered in cervical lymph. Am J Physiol 1999, 276:R1018\u2013R1022.","journal-title":"Am J Physiol"},{"key":"100_CR34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1086\/505539","volume":"79","author":"M Kawashima","year":"2006","unstructured":"Kawashima M, Tamiya G, Oka A, et al.: Genomewide association analysis of human narcolepsy and a new resistance gene. Am J Hum Genet 2006, 79:252\u2013263.","journal-title":"Am J Hum Genet"},{"key":"100_CR35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/ng1174","volume":"34","author":"M Tafti","year":"2003","unstructured":"Tafti M, Petit B, Chollet D, et al.: Deficiency in short-chain fatty acid beta-oxidation affects theta oscillations during sleep. Nat Genet 2003, 34:320\u2013325.","journal-title":"Nat Genet"},{"key":"100_CR36","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/ng.372","volume":"41","author":"J Hallmayer","year":"2009","unstructured":"Hallmayer J, Faraco J, Lin L, et al.: Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009, 41:708\u2013711.","journal-title":"Nat Genet"},{"key":"100_CR37","doi-asserted-by":"crossref","unstructured":"\u2022 Verma A, Anand V, Verma NP: Sleep disorders in chronic traumatic brain injury. J Clin Sleep Med 2007, 3:357\u2013362. This article identifies percentages of US patients among several million with chronic brain injury who report sleep problems and symptomatic EDS, underscoring the clinical relevance of symptomatic EDS.","DOI":"10.5664\/jcsm.26856"},{"key":"100_CR38","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/WNL.56.12.1751","volume":"56","author":"TE Scammell","year":"2001","unstructured":"Scammell TE, Nishino S, Mignot E, et al.: Narcolepsy and low CFS orexin (hypocretin) concentration after diencephalic stroke. Neurology 2001, 56:1751\u20131753.","journal-title":"Neurology"},{"key":"100_CR39","unstructured":"Marcus CL, Trescher WH, Halbower AC, et al.: Secondary narcolepsy in children with brain tumors. Sleep 200, 25:435\u2013459."},{"key":"100_CR40","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1212\/01.WNL.0000081049.14098.50","volume":"61","author":"S Nishino","year":"2003","unstructured":"Nishino S, Kanbayashi T, Fujiki N, et al.: CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies. Neurology 2003, 61:823\u2013825.","journal-title":"Neurology"},{"key":"100_CR41","unstructured":"Overeem S, Dalmau J, Bataller L, et al.: Secondary narcolepsy in patients with paraneoplastic anti-Ma2 antibodies is associated with hypocretin deficiency. J Sleep Res 2001, 11(Suppl.1):166\u2013167."},{"key":"100_CR42","doi-asserted-by":"crossref","unstructured":"\u2022 Kanbayashi T, Shimohata T, Nakashima I, et al.: Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 2009, 66(12):1563\u20131566. The authors report a significant recent study of symptomatic narcolepsy in patients diagnosed with immune-mediated neurologic condition MS with bilateral hypothalamic inflammatory lesions. The findings specifically link the presence of anti-AQP4 antibody and the probability of immuno-attack in hypothalamic periventricular regions to reduced CSF hypocretin-1 levels. Further, they suggest that additional antibody-mediated mechanisms also contribute to secondary hypocretin system impairment, manifesting in EDS symptoms.","DOI":"10.1001\/archneurol.2009.264"},{"key":"100_CR43","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1212\/WNL.57.12.2253","volume":"57","author":"B Ripley","year":"2001","unstructured":"Ripley B, Fujiki N, Okura M, et al.: CSF hypocretin\/orexin levels in narcolepsy and other neurological conditions. Neurology 2001, 57:2253\u20132258.","journal-title":"Neurology"},{"key":"100_CR44","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000117070","volume":"34","author":"N Tachibana","year":"1994","unstructured":"Tachibana N, Howar RS, Hirsch NP, et al.: Sleep problems in multiple sclerosis. Eur Neurol 1994, 34:320\u2013323.","journal-title":"Eur Neurol"},{"key":"100_CR45","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nrn1252","volume":"4","author":"M Amiry-Moghaddam","year":"2003","unstructured":"Amiry-Moghaddam M, Ottersen, OP: The molecular basis of water transport in the brain. Nat Rev Neurosci 2003, 4:991\u20131001.","journal-title":"Nat Rev Neurosci"},{"key":"100_CR46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, et al.: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473\u2013477.","journal-title":"J Exp Med"},{"key":"100_CR47","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/sleep\/26.8.953","volume":"6","author":"N Fujiki","year":"2003","unstructured":"Fujiki N, Ripley B, Yoshida Y, et al.: Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog. Sleep 2003, 6:953\u2013959.","journal-title":"Sleep"},{"key":"100_CR48","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1073\/pnas.0400590101","volume":"101","author":"M Mieda","year":"2004","unstructured":"Mieda M, Willie JT, Hara J, et al.: Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004, 101:4649\u20134654.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"100_CR49","unstructured":"\u2022 Mishima K, Fujiki N, Yoshida Y, et al.: Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. Sleep 2008, 31:1119\u20131126. This study demonstrated that supplementation of hypocretin-1 by central administration normalized sleep\/wake patterns and behavioral arrest episodes in hypocretin cell\u2013ablated narcoleptic (orexin\/ataxin-3) mice. It further demonstrated that exogenous expression of the prepro-hypocretin gene rescued sleep fragmentation and cataplexy in the mice, thus supporting further research aimed toward developing cell transplantation and gene therapy treatment options."},{"key":"100_CR50","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1006\/nbdi.2001.0389","volume":"8","author":"B Ripley","year":"2001","unstructured":"Ripley B, Fujiki N, Okura M, et al.: Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 2001, 8:525\u2013534.","journal-title":"Neurobiol Dis"},{"key":"100_CR51","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1939-1676.2004.tb02590.x","volume":"18","author":"SJ Schatzberg","year":"2004","unstructured":"Schatzberg SJ, Cutter-Schatzberg K, Nydam D, et al.: Case study: effect of hypocretin ligand replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Vet Intern Med 2004, 18:586\u2013588.","journal-title":"J Vet Intern Med"},{"key":"100_CR52","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1111\/j.1460-9568.2008.06446.x","volume":"28","author":"M Liu","year":"2008","unstructured":"Liu M, Thankachan S, Kaur S, et al.: Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice. Eur J Neurosci 2008, 28:1382\u20131393.","journal-title":"Eur J Neurosci"},{"key":"100_CR53","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/sleep\/27.8.1465","volume":"27","author":"O Arias-Carrion","year":"2004","unstructured":"Arias-Carrion O, Murillo-Rodriguez E, Xu M, et al.: Transplant of hypocretin neurons into the pontine reticular formation: primary results. Sleep 2004, 27:1465\u20131470.","journal-title":"Sleep"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-010-0100-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-010-0100-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-010-0100-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T11:31:06Z","timestamp":1591183866000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-010-0100-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,1]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["100"],"URL":"https:\/\/doi.org\/10.1007\/s11910-010-0100-z","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,1]]}}}